At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
Rituximab +1 moredrug
Likely dose
Rituximab 375mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
B Cell Targeted Treatment In Myasthenia Gravis (BeatMG): A Phase II Trial of Rituximab In Myasthenia Gravis
In Brief
A Phase 2 clinical trial evaluating Rituximab and Placebo for Myasthenia Gravis. Completed, enrolled 52 participants across 26 sites.
Detailed Summary
The specific primary objective of this study is to determine whether rituximab is a safe and beneficial therapeutic for Myasthenia Gravis (MG) that warrants further study in a phase III efficacy trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyasthenia Gravis
CountriesUnited States
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartMay 2014
Primary CompletionJul 2017
Study CompletionMay 2018
TodayJul 2026
First PostedApr 10, 2014
Enrollment StartMay 1, 2014
Primary CompletionJul 1, 2017
Study CompletionMay 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 12.2 years ago
Interventions
Rituximabdrug
Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
Placebodrug
The placebo group will receive a vehicle control infusion